Emerson (NYSE:EMR) Acquires National Instruments for $60 a Share
Market News

Emerson (NYSE:EMR) Acquires National Instruments for $60 a Share

Story Highlights

Emerson could soon announce a deal to acquire National Instruments. It could offer $60 a share to NATI shareholders.

Last updated: 10:08AM EST

National Instruments (NASDAQ:NATI) was up in morning trading on Wednesday after it was acquired by Emerson Electric (NYSE:EMR) for a total value of $8.2 billion at $60 per share in cash.

Lal Karsanbhai, President and CEO of Emerson commented, “With this expansion into test and measurement, Emerson will enhance its automation capabilities and gain a broader set of customers that relies on NI’s solutions at critical points along the product development cycle.”

First published:2:24AM EST

Bloomberg reported that Emerson Electric (NYSE:EMR) is inching closer to acquiring National Instruments (NASDAQ:NATI) for $60 a share. National Instrument makes automated test and measurement applications and virtual instrumentation software. 

According to the report, Emerson, which went past Fortive Corp. (NYSE:FTV), which was also in the race to acquire NATI, could announce a deal as soon as this week. Emerson has been pursuing this deal for a considerable amount of time. Earlier, during the Q1 conference call, EMR said it offered NATI $53 a share for acquisition. 

The move is part of Emerson’s strategy to create a company with a diversified and sustainable portfolio. Notably, this tech and engineering company is in the middle of a business transformation plan wherein it focuses on optimizing its portfolio to capitalize on high-growth industry verticals and technology segments. 

In 2022, Emerson combined its industrial software businesses with AspenTech (NASDAQ:AZPN). It owns the majority stake in the company (about 55%). Also, it acquired Fluxa. 

What’s the Prediction for EMR Stock?

Emerson’s focus on portfolio optimization and order growth will drive its revenue and earnings. Further, EMR is a Dividend Aristocrat and has increased its dividends for 66 years. However, Wall Street analysts are cautiously optimistic about EMR stock due to the macro uncertainty. 

It sports a Moderate Buy consensus rating on TipRanks based on six Buys and six Holds. Meanwhile, these analysts’ average price target of $99.18 implies 17.46% upside potential. 

Disclosure 

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles